Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 3,900 trials

Focal-Onset Seizures: Study of XEN1101

We are testing a new medication, XEN1101, to see if it can help reduce the frequency of focal-onset seizures. This study compares its effects to a placebo in participants with this condition.

Focal Epilepsy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hydroceles and Spermatoceles: Comparing Sclerotherapy Treatments

We are studying two methods of sclerotherapy to see which one better reduces symptoms and requires fewer follow-up treatments. This trial also looks at pain levels during the procedure with and without local anesthesia.

SpermatoceleHydrocele>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesUrology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

XEN1101 for Primary Generalized Tonic-Clonic Seizures

We are studying whether XEN1101 can help reduce the frequency of seizures in people with Primary Generalized Tonic-Clonic Seizures compared to a placebo. This trial aims to understand its safety and impact on seizure control.

Generalized Tonic-Clonic SeizureConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Lupus in Children: Anifrolumab Study

We are studying the safety and effectiveness of anifrolumab in children and teens with moderate to severe lupus. This trial aims to find the right dose and see how well it works compared to a placebo.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemotePediatricsRheumatology

Patient-Controlled Sedation for Perineal Laceration Repair

We are studying if adding propofol sedation improves comfort for women during the repair of grade I and II obstetric perineal lacerations. This trial aims to see if it reduces pain and discomfort compared to standard care.

Obstetric Perineal Lacerations6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOtolaryngology

Lymphoma Treatment: STP938

We are testing a new drug called STP938 for adults with relapsed or refractory B-cell and T-cell lymphomas. The goal is to see if it can provide a new treatment option for those who have not responded to other therapies.

B-cell LymphomaT-cell Lymphoma>2 yearsSafety phase (I)HematologyOncology

B-cell Acute Lymphoblastic Leukemia: UCART22 Treatment Study

We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Cancer Treatment: HRO761 for Specific Genetic Changes

We are studying the effects of HRO761 in cancer patients with certain DNA alterations known as Microsatellite Instability-High or Mismatch Repair Deficiency. This trial will help us understand how well this treatment works alone and with other therapies.

Microsatellite Instability (MSI) and Mismatch Repair Cancer Syndrome>2 yearsSafety phase (I)Oncology

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Alpha ThalassemiaEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteHematology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

THC Oil for Chronic Neuropathic Pain

We are studying the effects of THC 2% oil on pain relief in patients with chronic neuropathic pain. The trial will also explore how different patient traits may influence the treatment's effectiveness and safety.

Neuropathic Pain≤3 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteInternal MedicineNeurology

Breast Cancer Treatment: Tucatinib and Capecitabine

We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.

HER2-Amplified Metastatic Breast Cancer with Leptomeningeal Metastases>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Triple Negative Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are investigating the safety and effectiveness of a new treatment for patients with triple negative metastatic breast cancer whose disease has worsened after prior therapies. This study will help us learn more about how well this treatment works and its safety profile.

Triple Negative Metastatic Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Prostate Cancer: New Treatment Approach with Hormone Therapy

We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.

Oligorecurrent Hormone-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncologyUrology

Advanced Cancers: KFA115 Treatment Study

We are exploring a new drug, KFA115, alone and with pembrolizumab for patients with advanced cancers. The goal is to understand its safety and how well it works.

Epithelial Ovarian CancerThymic CarcinomaMesothelioma1-2 yearsSafety phase (I)Oncology

Pancreatic Cancer: New Treatment Combination Study

We are studying a new treatment combining autogene cevumeran, atezolizumab, and mFOLFIRINOX for patients with resected pancreatic ductal adenocarcinoma. The goal is to see if this combination improves survival compared to standard mFOLFIRINOX alone.

Pancreatic Cancer>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessCost ReimbursementOncology